Skip to content

Trial · Interventional

Active, not recruitingPhase 3Registry data

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

NCTNCT06948435 (opens ClinicalTrials.gov in a new tab)Other id27359Other idJ2A-MC-GZL1Other idJ2A-MC-GZPL
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Active, not recruiting
Phase
Phase 3
Enrollment
487 participants (estimated)
Sponsor
Eli Lilly and Company · Industry
Design
Randomized · Double masking
Countries
11 countries

United States, Argentina, China, Czechia, Germany, Greece, India, Japan, Poland, Puerto Rico, Spain

Start
30 Apr 2025
Primary completion
Sept 2027 (estimated)
Completion
Sept 2027 (estimated)
First posted
29 Apr 2025
Last update posted
29 May 2026
Conditions
Hypertension · Overweight or Obesity

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2025202620272028
  1. Ph 3

    A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

    NCT06948435

    30 Apr 2025 to est. Sept 2027

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

Interventions

  • OrforglipronDrug
  • PlaceboDrug

Arms2

  • Experimental

    Orforglipron

    Participants will receive orforglipron orally.

  • Placebo comparator

    Placebo

    Administered placebo.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change from Baseline in office Systolic Blood Pressure (SBP)

    Time frame · Baseline to Week 36

Secondary outcomes(7)

  1. Change from Baseline in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) SBP

    Time frame · Baseline to Week 36

  2. Percent Change from Baseline in Body Weight

    Time frame · Baseline to Week 36

  3. Percent Change from Baseline in Triglycerides

    Time frame · Baseline to Week 36

  4. Percent Change from Baseline in non-HDL Cholesterol

    Time frame · Baseline to Week 36

  5. Percent Change from Baseline in hsCRP Concentration (mg/L)

    Time frame · Baseline to Week 48

  6. Change in office SBP in Randomized Withdrawal Population

    Time frame · Week 48 to Week 60

  7. Pharmacokinetics (PK): Steady-State Area Under the Concentration Curve (AUC) of Orforglipron

    Time frame · Baseline to Week 36

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * refer to the GZPL master protocol for screening eligibility. Exclusion Criteria: * refer to the GZPL master protocol for screening eligibility.

PepBank is a research reference. Talk to a doctor before you use any peptide.